Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134003) titled 'Efficacy and Safety of Ultra-low-dose Radiotherapy Combined with Zuberitamab for Limited Stage MALT' on Oct. 10.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Condition:
Mucosa-associated lymphoid tissue (MALT) lymphoma, limited stage, including gastric MALT lymphoma and non-gastric limited-stage MALT lymphoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-10-10
Target Sample Size: Trial group: zuberitamab combined with ultra-low-dose radiotherapy:73;
Cou...